Lung cancer: Bortezomib extends survival 22 percent
Results of the Southwest Oncology Group study, led by UC Davis Cancer Center researchers have shown that adding Bortezomib ( Velcade ) to a standard chemotherapy regimen of Gemcitabine and Carboplatin prolongs survival in patients with advanced non-small cell lung cancer.
This entry was posted on Tuesday, August 22nd, 2006 at 5:24 pm and is filed under Research, Non-Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.